### TEMPUR + SEALY

January 24, 2012

### Tempur-Pedic Reports Record Fourth Quarter and Full Year Sales and Earnings

- -- Reports Fourth Quarter Sales Up 25% and EPS Up 27% at \$0.84
- -- Announces New \$250 Million Share Repurchase Program
- -- Issues Financial Guidance For 2012

LEXINGTON, Ky., Jan. 24, 2012 /PRNewswire/ -- Tempur-Pedic International Inc. (NYSE: TPX), the leading manufacturer, marketer and distributor of premium mattresses and pillows worldwide, today announced financial results for the fourth quarter and year ended December 31, 2011. The Company also announced a \$250 million share repurchase program and issued financial guidance for 2012.

### FOURTH QUARTER FINANCIAL SUMMARY

- Earnings per diluted share (EPS) were \$0.84 in the fourth quarter of 2011 as compared to EPS of \$0.66 per diluted share in the fourth quarter of 2010. The Company reported net income of \$56.3 million for the fourth quarter of 2011 as compared to net income of \$46.3 million in the fourth quarter of 2010.
- Net sales increased 25% to \$366.8 million in the fourth quarter of 2011 from \$292.7 million in the fourth quarter of 2010.
   On a constant currency basis, net sales increased 24%. Net sales in the North American segment increased 26% and international segment net sales increased 25%. On a constant currency basis, international segment net sales increased 21%.
- Mattress sales increased 26% globally. Mattress sales increased 24% in the North American segment and increased 33% in the international segment. On a constant currency basis, international mattress sales increased 29%. Pillow sales increased 16% globally. Pillow sales increased 15% in North America and 17% internationally. On a constant currency basis, international pillow sales increased 13%.
- Gross profit margin was 52.1% as compared to 51.9% in the fourth quarter of 2010. The gross profit margin increased as a result of favorable mix, improved efficiencies in manufacturing and distribution, and fixed cost leverage related to higher production volumes, partially offset by higher commodity costs and costs associated with US shipments to support the Company's Danish manufacturing facility.
- Operating profit margin was 23.4% as compared to 24.5% in the fourth quarter of 2010 reflecting the Company's strategic investments to drive growth, including brand advertising.
- The Company generated \$69.7 million of operating cash flow as compared to \$44.5 million in the fourth quarter of 2010.
- During the fourth quarter of 2011, the Company purchased 2.3 million shares of its common stock for a total cost of \$128.5 million.

### **FULL YEAR FINANCIAL SUMMARY**

- Earnings per share (EPS) were \$3.18 per diluted share for the full year 2011 as compared to EPS of \$2.16 per diluted share for the full year 2010. The Company reported net income of \$219.6 million for the full year 2011 as compared to net income of \$157.1 million for the full year 2010.
- Net sales increased 28% to \$1,417.9 million for the full year 2011 from \$1,105.4 million for the full year 2010. On a
  constant currency basis, net sales increased 25%. Net sales in the North American segment increased 30% and

international segment net sales increased 24%. On a constant currency basis, international segment net sales increased 16%.

- Gross profit margin was 52.4% for the full year 2011 as compared to 50.2% for the full year 2010. The gross profit
  margin increased as a result of favorable mix, improved efficiencies in manufacturing and distribution, and fixed cost
  leverage related to higher production volumes, partially offset by higher commodity costs, new product introductions, and
  costs associated with US shipments to support the Company's Danish manufacturing facility.
- Operating profit margin was 24.0% as compared to 22.2% for the full year 2010.
- The Company generated \$248.7 million of operating cash flow as compared to \$184.1 million for the full year 2010.
- During 2011, the Company purchased 6.5 million shares of its common stock for a total cost of \$368.5 million.

Chief Executive Officer Mark Sarvary commented, "In 2011, we delivered strong financial performance, strengthened our competitiveness and implemented a range of strategic growth initiatives. Over the next year, we plan to increase our rate of investment in areas that will drive growth including a major new product launch, increased advertising, and expanded distribution. In addition, to ensure Tempur continues to deliver the best sleep, our R&D team is focused on executing a broad technology strategy that includes a focus on improving existing product performance and lowering costs as well as another major new product launch in 2013."

### **Share Repurchase Program**

The Company announced the Board of Directors has authorized a new share repurchase program of up to \$250.0 million. This share repurchase program replaces the Company's prior share repurchase authorization, and may be limited, suspended or terminated at any time without prior notice. Stock repurchases under this program may be made through open market transactions, negotiated purchases or otherwise, at times and in such amounts as management and a committee of the Board deem appropriate. The timing and actual number of shares repurchased will depend on a variety of factors including price, financing and regulatory requirements and other market conditions. Repurchases may also be made under a Rule 10b5-1 plan, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws.

### **Financial Guidance**

The Company issued full year 2012 guidance for net sales and earnings per share. It currently expects net sales for 2012 to range from \$1.60 billion to \$1.65 billion. It currently expects EPS for 2012 to range from \$3.80 to \$3.95 per diluted share. The Company noted its expectations are based on information available at the time of this release, and are subject to changing conditions, many of which are outside the Company's control. The Company noted its EPS guidance does not assume any benefit from a potential reduction in shares outstanding related to its share repurchase program.

### **Conference Call Information**

Tempur-Pedic International will host a live conference call to discuss financial results today, January 24, 2012 at 5:00 p.m. Eastern Time. The dial-in number for the conference call is 800-850-2903. The dial-in number for international callers is 224-357-2399. The call is also being webcast and can be accessed on the investor relations section of the Company's website, <a href="http://www.tempurpedic.com">http://www.tempurpedic.com</a>. After the conference call, a webcast replay will remain available on the investor relations section of the Company's website for 30 days.

### **Forward-looking Statements**

This release contains "forward-looking statements," within the meaning of federal securities laws, which include information concerning one or more of the Company's plans, objectives, goals, strategies, and other information that is not historical information. When used in this release, the words "estimates," "expects," "anticipates," "projects," "plans," "intends," "believes," and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to the Company's plans to increase its rate of investment in areas to drive growth, the Company's R&D strategy and expected product launches and expectations for net sales and earnings per share for 2012. All forward looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company will realize these expectations or that these beliefs will prove correct.

There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained in this release. Numerous factors, many of which are beyond the Company's control, could cause actual results to differ materially from those expressed as forward-looking statements. These risk factors include general economic, financial and industry conditions, particularly in the retail sector, as well as consumer confidence and the availability of consumer financing; uncertainties arising from global events; the effects of changes in foreign exchange rates on the Company's reported earnings; consumer acceptance of the Company's products; industry competition; the efficiency and effectiveness of the Company's advertising campaigns and other marketing programs; the Company's ability to increase sales productivity within existing retail accounts and to further penetrate the Company's retail channel, including the timing of opening or expanding within large retail accounts; the Company's ability to expand brand awareness, distribution and new products in international markets; the Company's ability to continuously improve and expand its product line, maintain efficient, timely and cost-effective production and delivery of its products, and manage its growth; the effects of strategic investments on our operations; changes in foreign tax rates, including the ability to utilize tax loss carry forwards; and rising commodity costs. Additional information concerning these and other risks and uncertainties are discussed in the Company's filings with the Securities and Exchange Commission, including without limitation the Company's Annual Report on Form 10-K under the headings "Special Note Regarding Forward-Looking Statements" and "Risk Factors." Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements for any reason, including to reflect events or circumstances after the date on which such statements are made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

### **About the Company**

Tempur-Pedic International Inc. (NYSE: TPX) manufactures and distributes mattresses and pillows made from its proprietary TEMPUR(R) pressure-relieving material. It is the worldwide leader in premium and specialty sleep. The Company is focused on developing, manufacturing and marketing advanced sleep surfaces that help improve the quality of life for people around the world. The Company's products are currently sold in over 80 countries under the TEMPUR(R) and Tempur-Pedic(R) brand names. World headquarters for Tempur-Pedic International is in Lexington, KY. For more information, visit <a href="http://www.tempurpedic.com">http://www.tempurpedic.com</a> or call 800-805-3635.

### TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES Consolidated Statements of Income (In thousands, except per common share amounts)

	Three Months Ended December 31,								
		2011		2010	Chg %		2011	 2010	Chg %
Net sales	\$	366,803	\$	292,703	25.3%	\$	1,417,938	\$ 1,105,421	28.3%
Cost of sales		175,635		140,880			674,848	 549,994	
Gross profit									
		191,168		151,823	25.9%		743,090	555,427	33.8%
Selling and marketing expenses		72,081		53,449			276,870	199,722	
General, administrative and other expenses		33,273	_	26,766			125,689	 109,803	
Operating income	85			71,608	19.8%		340,531	245,902	38.5%
Other expense, net:									
Interest expense, net		(3,498)		(3,458)			(11,948)	(14,501)	
Other income (expense), net		758		32			(192)	 (536)	
Total other expense		(2,740)		(3,426)			(12,140)	(15,037)	
Income before income taxes		83,074		68,182	21.8%		328,391	230,865	42.2%
Income tax provision		26,759		21,890			108,783	 73,720	
Net income	\$	56,315	\$	46,292		\$	219,608	\$ 157,145	
Earnings per common share:									
Basic	\$	0.86	\$	0.68		\$	3.27	\$ 2.23	
Diluted	\$	0.84	\$	0.66		\$	3.18	\$ 2.16	
Weighted average common shares outstanding:			-					 	
Basic		65,113		68,220			67,070	 70,348	
Diluted		66,953		70,619			69,149	 72,792	
		· <u> </u>		<del></del>			<del></del>	 <del></del> -	

## TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES Consolidated Balance Sheets (In thousands)

(iii tiiousailus)					
	December 31,	December 31			
	2011	2010			
ASSETS		-			
Current Assets:					
Cash and cash equivalents	\$ 111,367	\$ 53,623			
Accounts receivable, net	142,412	115,630			
Inventories	91,212	69,856			
Prepaid expenses and other current assets	20,088	18,646			
Deferred income taxes	14,391	13,725			
Total Current Assets	379,470	271,480			
Property, plant and equipment, net	160,502	159,807			
Goodwill	213,273	212,468			
Other intangible assets, net	66,491	68,745			
Other initialigible assets, riet Other non-current assets	8,904	3,503			
Total Assets	\$ 828,640	\$ 716,003			
Total Assets	Ψ 020,040	Ψ 710,000			
Current Liabilities:  Accounts payable  Accrued expenses and other current liabilities	\$ 69,936 92,737	\$ 48,288 85,469			
·	•	•			
Income taxes payable  Total Current Liabilities	20,506 183,179	12,477			
Total Current Liabilities	103,179	140,234			
Long-term debt	585,000	407,000			
Deferred income taxes	24,227	32,315			
Other non-current liabilities	5,443	4,421			
Total Liabilities	797,849	589,970			
Stockholders' Equity:					
Common stock, \$0.01 par value; 300,000 shares	200	000			
authorized; 99,215 shares issued as of December 31, 2011 and 2010	992	992			
Additional paid in capital	361,807	320,952			
Retained earnings	742,480	522,872			
Accumulated other comprehensive loss Treasury stock at cost; 35,445 and 30,731 shares as of	(14,686)	(6,188)			
December 31, 2011 and 2010, respectively	(1,059,802)	(712,595)			
Fotal Stockholders' Equity	30,791	126,033			
and a second second — denty		.23,300			
Total Liabilities and Stockholders' Equity	\$ 828,640	\$ 716,003			

# TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES Consolidated Statements of Cash Flows (In thousands)

		Twelve Months Ended December 31,				
			2011		2010	
CASH FLOWS FROM OPERATING ACTIVITIES:	- -			- ' <u></u>		
Net income		\$	219,608	\$	157,145	
Adjustments to reconcile net income to net cash provided	by operating activities:					
Depreciation and amortization			34,295		32,361	
Amortization of stock-based compensation			16,693		11,608	
Amortization of deferred financing costs			1,034		690	
Bad debt expense			1,563		531	
Deferred income taxes			(8,528)		4,946	
Foreign currency adjustments and other			1,248		(465)	
Changes in operating assets and liabilities						

Accounts receivable	(30,198)	(12,752)
Inventories	(18,473)	(6,710)
Prepaid expense and other current assets	(2,772)	(6,519)
Accounts payable	21,675	(1,145)
Accrued expenses and other	3,867	(370)
Income taxes payable	8,694	4,802
Net cash provided by operating activities	248,706	184,122
CASH FLOWS FROM INVESTING ACTIVITIES:		
Acquisition of business, net of cash acquired	(4,566)	(18,692)
Acquisition of trademarks and other	(2,044)	(684)
Purchases of property, plant and equipment	(29,466)	(18,141)
Net cash used by investing activities	(36,076)	(37,517)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from long-term revolving credit facility	821,500	308,836
Repayments of long-term revolving credit facility	(643,500)	(197,813)
Payments of deferred finance costs	(6,217)	-
Proceeds from issuance of common stock	26,256	28,551
Excess tax benefit from stock-based compensation	19,192	5,590
Treasury shares repurchased	(365,928)	(250,000)
Other	(173)	(1,540)
Net cash used by financing activities	(148,870)	(106,376)
NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(6,016)	(648)
Increase in cash and cash equivalents	57,744	39,581
CASH AND CASH EQUIVALENTS, beginning of period	53,623	14,042
CASH AND CASH EQUIVALENTS, end of period	\$ 111,367	\$ 53,623

### **Summary of Channel Sales**

The following table highlights net sales information, by channel and by segment:

(In thousands)

	CONSOLIDATED  Three Months Ended  December 31,				NORTH AMERICA Three Months Ended December 31,				INTERNATIONAL Three Months Ended December 31,			
	2011	2010		2010		2011	2010		2011		2010	
Retail	\$ 319,334	\$	254,565	\$	225,197	\$	180,756	\$	94,137	\$	73,809	
Direct	28,609		19,184		21,143		14,718		7,466		4,466	
Healthcare	8,987		9,212		2,953		3,090		6,034		6,122	
<b>Third Party</b>	9,873		9,742	_			-		9,873		9,742	
	\$ 366,803	\$	292,703	\$	249,293	\$	198,564	\$	117,510	\$	94,139	

### **Summary of Product Sales**

The following table highlights net sales information, by product and by segment:

(In thousands)

	7	CONSOLIDATED Three Months Ended December 31,			7	NORTH AMERICA Three Months Ended December 31,				INTERNATIONAL Three Months Ended December 31,			
		2011		2010		2011		2010		2011		2010	
Mattresses Pillows	\$	238,590 43,971	\$	188,732 37,934	\$	166,009 22,067	\$	134,186 19,234	\$	72,581 21,904	\$	54,546 18,700	

 84,242
 66,037
 61,217
 45,144
 23,025
 20,893

 \$ 366,803
 \$ 292,703
 \$ 249,293
 \$ 198,564
 \$ 117,510
 \$ 94,139

# TEMPUR-PEDIC INTERNATIONAL INC. AND SUBSIDIARIES Reconciliation of EBITDA to Net Income and Total debt to Funded debt Non-GAAP Measures (In thousands)

The Company provides information regarding Earnings Before Interest Taxes Depreciation and Amortization (EBITDA) and Funded debt which are not recognized terms under U.S. GAAP (Generally Accepted Accounting Principles) and do not purport to be alternatives to Net income as a measure of operating performance or Total debt. A reconciliation of EBITDA to the Company's Net income and a reconciliation of Total debt to Funded debt are provided below. Management believes that the use of EBITDA and Funded debt provides investors with useful information with respect to the terms of the Company's credit facility.

#### Reconciliation of Net income to EBITDA

The following table sets forth the reconciliation of the Company's reported Net income to the calculation of EBITDA for the twelve months ended December 31, 2011:

	Twelve Months Ended
	December 31, 2011
GAAP Net income	\$ 219,608
Plus:	
Interest expense	11,948
Income taxes Depreciation &	108,783
Amortization	50,988
EBITDA	\$ 391,327

### Reconciliation of Total debt to Funded debt

The following table sets forth the reconciliation of the Company's reported Total debt to the calculation of Funded debt as of December 31, 2011:

	As of December 31, 2011
GAAP basis Total debt Plus:	\$ 585,000
Letters of credit outstanding	990
Funded debt	\$ 585,990

### Calculation of Funded debt to EBITDA

	As of
	December 31, 2011
Funded debt	\$ 585,990
EBITDA	391,327
	1.50 times

SOURCE Tempur-Pedic International Inc.

News Provided by Acquire Media